Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity

US7776862B2 · kind B2 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Brian F. McGuinness · Plainsboro, US
• Stuart B. Rosenblum · West Orange, US
• Joseph A. Kozlowski · Princeton, US
• Gopinadhan N. Anilkumar · Edison, US
• Seong Heon Kim · Livingston, US
• Neng-Yang Shih · Lexington, US
• Chung-Her Jenh · Edison, US
• Paul J. Zavodny · Mountainside, US
• Douglas W. Hobbs · Yardley, US
• Guizhen Dong
• Yuefei Shao · Princeton, US
• Lisa Guise Zawacki · Yardley, US
• Cangmeng Yang · Highland Park, US
• Carolyn Dilanni Carroll · Yardley, US

Key dates

• Filing date: Feb 14, 2006
• Grant date: Aug 17, 2010
• Expiry date: Oct 3, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1:and the pharmaceutically acceptable salts, solvates and esters thereof. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.